Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740981 | 0.78 | PTGES2 (0.58) | ALDH1A1GAAMAPTKDM4ELMNA | |
| SCHEMBL20627051 | 0.75 | POLB (0.53) | ALDH1A1ATMGAAUSP2POLB | |
| SCHEMBL16735251 | 0.74 | LMNA (0.62) | ALDH1A1GAAMAPTPOLBHSD17B10 | |
| SCHEMBL2740996 | 0.72 | PTGES2 (0.56) | MAPTPOLBKDM4ESMN1; SMN2 | |
| SCHEMBL7210060 | 0.71 | LMNA (0.69) | ALDH1A1GAAPOLBHSD17B10KDM4E | |
| SCHEMBL2740982 | 0.70 | SLC22A12 (0.68) | — | |
| SCHEMBL1459692 | 0.69 | SMN1; SMN2 (0.71) | ALDH1A1GAAMAPTPOLBHSD17B10 | |
| SCHEMBL2171063 | 0.68 | MAPT (0.44) | ALDH1A1GAAMAPTPOLBKDM4E | |
| SCHEMBL3247291 | 0.68 | CNR1 (0.56) | GAAMAPTUSP2POLBL3MBTL1 | |
| SCHEMBL2740980 | 0.68 | KDM4E (0.54) | ALDH1A1HSD17B10KDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088772-B2 | Sulfonamides and their use as a medicament | THE GENETICS COMPANY, INC. (CH) | 2012-01-03 | — | — | US | disclosed |
| US-8088772-B2 | Sulfonamides and their use as a medicament | THE GENETICS COMPANY, INC. (CH) | 2012-01-03 | — | — | US | disclosed |
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | THE GENETICS COMPANY, INC. (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | THE GENETICS COMPANY, INC. (CH) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | BCOR, CBR3, SULT1E1 | ALDH1A1 3484/4885ATM 3562/4885GAA 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.